In another WT1 peptide vaccine trial among a group of 20 children with glioma, rhabdomyosarcoma, neuroblastoma, osteosarcoma, and clear cell sarcoma of the kidney (63), WT1-specific immune response was demonstrated in 4/18 (22%) evaluable patients (63). Here, WT1 is linked to clear cell sarcoma of kidney.